| Serotype | No Positive/TOT | Observed seroprevalence †| 95%CI |
---|---|---|---|---|
West Africa | A | 6/12 | 50.0% | 25.4% - 74.6% |
 | O | 6/12 | 50.0% | 25.4% - 74.6% |
 | C | 7/12 | 58.3% | 31.9% - 80.7% |
 | SAT 1 | 8/12 | 66.7% | 38.8% - 86.4% |
 | SAT 2 | 9/12 | 75.0% | 46.1% - 91.7% |
 | SAT 3 | 3/12 | 25.0% | 8.3% - 53.8% |
Central Africa | A | 50/115 | 43.4% | 34.8% - 52.6% |
 | O | 96/112 | 85.7% | 77.9% - 91.1% |
 | C | 77/115 | 67.0% | 57.9% - 74.9% |
 | SAT 1 | 85/115 | 73.9% | 65.2% - 81.1% |
 | SAT 2 | 95/115 | 82.6% | 74.6% - 88.5% |
 | SAT 3 | 56/115 | 48.7% | 39.7% - 57.7% |
TOT | A | 56/127 | 44.1% | 35.8% - 52.8% |
 | O | 102/124 | 82.3% | 74.5% - 88.0% |
 | C | 84/127 | 66.1% | 57.5% - 73.8% |
 | SAT 1 | 93/127 | 73.2% | 64.9% - 80.2% |
 | SAT 2 | 104/127 | 81.9% | 74.2% - 87.7% |
 | SAT 3 | 59/127 | 46.5% | 38.0% - 55.1% |